Regulatory antibodies against GPCR in women ten years after early-onset preeclampsia


  • A. Birukov
  • H.E.C. Muijsers
  • H. Heidecke
  • J.T. Drost
  • M.W. Cunnigham
  • K. Kraker
  • N. Haase
  • A. Frolova
  • D.N. Müller
  • F. Herse
  • A.H.E.M. Maas
  • R. Dechend


  • Frontiers in Bioscience


  • Front Biosci 24: 1462-1476


  • Preeclampsia is associated with an increased cardiovascular risk later in life. Anti-GPCR autoantibodies have been shown to contribute to the development of cardiovascular disease. We investigated whether anti-GPCR autoantibodies are elevated in women with a history of early-onset preeclampsia 8-11 years postpartum, and whether they correlate with clinical outcomes. We investigated data from the Preeclampsia Risk EValuation in FEMales cohort, a retrospective matched case-control study. Anti AT1R-, beta1AR-, ETAR-, PAR1- and CXCR3- autoantibodies were determined in 485 samples by using commercially available ELISA. Women with the lowest combined levels of autoantibodies and a history of early preeclampsia had significantly higher SBP, DBP and MAP (all p<0.001) compared to the controls. The individual titer levels of autoantibodies were not different between controls and former early PE groups 8-11 years postpartum. In conclusion, regulatory autoantibodies alone are not sufficient to explain hypertension or other cardiovascular pathologic conditions, but together with other risk factors such as a previous hypertensive pregnancy, lower levels of autoantibodies are associated with increased blood pressure.